Skip to main content
    S

    Scienture Holdings, Inc. (SCNX)

    Official site

    HEALTHCARE • PHARMACEUTICAL RETAILERS • NASDAQ

    $3.24
    -0.67 (-17.14%)

    Market Cap: $5.50M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    36%(8/22)
    Avg Surprise
    -3033.65%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.50
    Range$-1.50 - $-1.50
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-4.50+66.7%
    60d ago$-2.00+25.0%
    30d ago$-2.00+25.0%
    7d ago$-2.00+25.0%
    Current$-1.50
    Revenue Consensus
    $2M
    Range$2M - $2M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-3.94
    Range$-3.94 - $-3.94
    1 analysts
    Revenue Consensus
    $3M
    Range$3M - $3M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-3.94---
    Sep 26EST
    		-$-1.50---
    Jun 26
    Reported Aug 13
    		$-0.07$-0.09+22.22%Beat+85.4%
    Mar 26
    Reported May 11
    		$-0.08N/A+63.64%Beat+75.4%
    Dec 25
    Reported Mar 24
    		$-0.13N/A+53.57%Beat+83.5%
    Sep 25
    Reported Nov 12
    		$-0.19$0.00N/AMiss+85.8%
    Jun 25
    Reported Aug 12
    		$-0.48N/AN/ABeat+63.2%
    Mar 25
    Reported May 12
    		$-0.33N/AN/ABeat-101.6%
    Dec 24
    Reported Mar 26
    		$-0.79$0.38-307.89%Miss+93.9%
    Sep 24
    Reported Nov 6
    		$-1.34N/AN/ABeat+70.7%
    Jun 24
    Reported Aug 9
    		$-1.30N/AN/ABeat+55.0%
    Mar 24
    Reported Jun 26
    		$20.49N/AN/ABeat+29375.4%
    Dec 23
    Reported Mar 25
    		$-12.95N/AN/ABeat-763.0%
    Sep 23
    Reported Oct 25
    		$-4.57N/AN/ABeat-407.9%
    Jun 23
    Reported Jul 24
    		$-2.90$-0.45-544.24%Miss-48.7%
    Mar 23
    Reported May 15
    		$-0.07$-0.02-250.00%Miss+96.1%
    Dec 22
    Reported Mar 31
    		$-1.50$-0.27-448.85%Miss+0.0%
    Sep 22
    Reported Nov 7
    		$-0.90$-0.12-682.61%Miss+62.5%
    Jun 22
    Reported Jul 25
    		$-1.95$-0.06-3445.45%Miss+59.4%
    Mar 22
    Reported May 9
    		$-1.80$-0.10-1761.43%Miss-50.0%
    Dec 21
    Reported Mar 31
    		$-1.50$-0.14-971.43%Miss+65.5%
    Sep 21
    Reported Oct 25
    		$-2.40$-0.12-1900.00%Miss-900.0%
    Jun 21
    Reported Jul 26
    		$-4.80$-0.09-5436.33%Miss-357.1%
    Mar 21
    Reported Apr 26
    		$-1.20$-0.06-2016.40%Miss-500.0%
    Dec 20
    Reported Mar 31
    		$-4.35$0.01-43600.00%Miss-262.5%
    Sep 20
    Reported Oct 26
    		$0.30$0.03+900.00%Beat+338.6%
    Jun 20
    Reported Jul 27
    		$-1.05$0.01-10600.00%Miss-831.7%
    Mar 20
    Reported May 4
    		$0.30$0.01+2900.00%Beat-4.2%
    Dec 19
    Reported Mar 25
    		$-1.20$0.06-2100.00%Miss-11900.0%
    Sep 19
    Reported Oct 31
    		$0.07$0.01+584.00%Beat-72.0%
    Jun 19
    Reported Jul 29
    		$0.14$0.01+1335.00%Beat+168.2%
    Mar 19
    Reported May 8
    		$0.31$0.02+1466.00%Beat+44.1%
    Dec 18
    Reported Mar 31
    		$-0.01N/AN/ABeat-102.5%
    Sep 18
    Reported Oct 26
    		$0.24N/AN/ABeat+21.4%
    Jun 18
    Reported Aug 9
    		$0.05N/AN/ABeat+377.2%
    Mar 18
    Reported May 9
    		$0.22N/AN/ABeat+3.8%
    Dec 17
    Reported Mar 31
    		$0.39N/AN/ABeat-
    Sep 17
    Reported Nov 13
    		$0.20N/AN/ABeat-
    Jun 17
    Reported Aug 7
    		$-0.02N/AN/ABeat-
    Mar 17
    Reported May 10
    		$0.21N/AN/ABeat-
    Dec 16
    Reported Mar 31
    		$0.00$0.00N/ABeat-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00

    Key Metrics

    Valuation
    P/E Ratio-0.28EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-786.00%
    ROE-53.50%ROIC-47.05%
    Financial Health
    Debt/Equity0.17xInterest Coverage-12.08x
    Current Ratio3.04xQuick Ratio2.97x
    Trading Statistics
    Beta4.08Avg Volume8.54M
    52-Week High$65.0052-Week Low$3.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.13
    SMA 20$5.74
    SMA 50$8.30
    SMA 200$9.83
    EMA 10$4.32
    EMA 20$5.46
    EMA 50$7.31
    EMA 200$10.96

    MACD

    Line: -1.43Signal: -1.29Hist: -0.14

    ADX

    ADX: 56.4+DI: 4.1-DI: 1.2

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down72.0
    PSAR$0.82

    Bollinger Bands

    Upper Band$9.33
    Lower Band$2.14
    %B Position12533%(Upper)
    Band Width0.15

    RSI (14-Day)

    Oversold
    16.5

    Momentum Oscillators

    Stoch %K84.9
    Stoch %D88.9
    Williams %R-24.7
    ROC (10d)-51.4%
    Momentum-3.42
    CCI (20d)59.8
    MFI (14d)0.6

    Volatility Measures

    ATR (14d)$4.77(147.2%)
    StdDev (20d)1.80
    Hist Vol135.3%(High)

    Volume Flow

    VWAP$3.47
    OBV781.1M
    AD Line305.5B
    CMF (20d)126.164

    Volume Metrics

    Avg Vol (20d)9.4M
    Vol Ratio0.1x(Low)
    VWMA (20d)$4.33

    Pivot Points

    R3$4.35
    R2$4.13
    R1$4.02
    Pivot Point$3.80
    S1$3.69
    S2$3.47
    S3$3.36

    Advanced Oscillators

    TSI-66.60
    Ultimate Osc64.0
    KST-520.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$343,639$56,325$-168,699$590,050$0$10,258$53,083$64,861$18,699$0$111,702$392,286
    Cost of Revenue$7,860$2,475$75,113$15,429$0$9,585$50,258$60,978$19,402$0$242,622$352,694
    Gross Profit$335,779$53,850$-243,812$574,621$0$673$2,825$3,883$-703$0$-130,920$39,592
    Operating Expenses$3.03M$3.55M$29.16M$4.94M$5.16M$3.57M$4.22M$3.50M$1.49M$5.49M$2.10M$801,270
    R&D$1.17M$793,984$368,698$169,344$843,549$574,679$982,707$1.25M$0$0$0$0
    SG&A$1.33M$2.01M$1.94M$3.49M$3.14M$1.77M$1.57M$762,013$924,557$4.88M$1.11M$362,377
    Operating Income$-2,699,733$-3,509,499$-29,500,413$-4,361,206$-5,157,906$-3,571,317$-4,214,562$-3,497,791$-1,495,691$-5,492,971$-2,228,901$-761,678
    Interest Income$147,147$133,344$212,992$1,120$63,148$25,442$1,940$29,445$41,031$62,921$0$0
    Interest Expense$269,785$37,019$955,499$1.80M$653,493$670,784$1.01M$217,433$4,949$98,515$648,319$251,778
    Income Before Tax$-2,822,371$-3,402,264$-30,115,211$-3,607,361$-6,720,573$-3,063,997$-7,337,112$-3,183,601$-1,624,741$-6,633,422$-5,029,056$-88,136
    Income Tax Expense$0$0$-1,994,878$0$0$0$-534,396$0$0$0$0$0
    Net Income$-2,822,371$-3,402,264$-28,120,333$-3,607,361$-6,720,573$-3,063,997$-7,162,732$-3,183,601$-1,833,902$21.25M$-11,665,629$-3,525,114
    EBITDA$-2,141,226$-3,030,576$-28,165,597$-42,748$-5,629,249$-1,894,513$-5,410,992$-2,959,797$-1,652,460$-6,589,525$-3,665,287$392,182
    EBIT$-2,699,733$-3,498,589$-29,031,054$-1,805,051$-6,130,228$-2,418,655$-6,324,318$-2,995,613$-1,660,823$-6,597,828$-4,380,737$163,642
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SCNX

    News

    4E4.HM Interactive Stock Chart | Scienture Holdings Inc. R Stock

    The article displays an interactive stock chart for Scienture Holdings Inc. (4E4.HM) on Yahoo Finance. It shows the stock's performance, indicating a delayed quote of EUR 0.1039, a decrease of 0.0387 euros...

    Yahoo Finance•10/14/26•Bearish

    SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

    SCIENTURE announced preliminary unaudited revenue of approximately $1.22 million for Q3 2026, marking a significant 256% sequential growth compared to Q2 2026. This growth is attributed to the continued execution of its...

    Moomoo•10/13/26•Neutral

    Scienture Slides on Q3 Figures

    Scienture Holdings, Inc. announced preliminary, unaudited revenue of approximately $1.22 million for Q3 2026, a 256% increase from Q2. This growth is attributed to the successful launch of REZENOPY™ and continued sales...

    Baystreet.ca•10/13/26•Somewhat-Bearish

    Scienture reports Q3 revenue of $1.22M, up 256% sequentially

    Scienture Holdings Inc. announced preliminary unaudited revenue of approximately $1.22 million for the third quarter ended September 30...

    Investing.com•10/13/26•Bullish

    EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

    Scienture Holdings Inc. reported a significant 256% increase in preliminary third-quarter revenue, reaching $1.22 million...

    Benzinga•10/13/26•Bullish

    SCNX Valuation and Fair Value

    P/E
    -0.3x
    Forward P/E
    21.8x
    P/B
    0.1x
    See GNG's fair value

    SCNX Profitability: Margins, ROIC and FCF

    Gross margin
    87.7%
    Operating margin
    -786.0%
    Net margin
    0.0%
    ROIC
    -47.0%
    ROE
    -53.5%
    FCF margin
    -1758.2%

    SCNX Competitors

    CompanyTicker
    Longeveron LLCLGVN
    Volitionrx LtdVNRX
    enVVeno Medical CorpNVNO
    Processa Pharmaceuticals IncPCSA
    Sonoma Pharmaceuticals IncSNOA
    Aptorum Group Ltd Class AAPM
    Imunon IncIMNN
    Trinity Biotech plcTRIB

    Sector: Healthcare

    SCNX Bull Case vs Bear Case

    Bull case

    • SCNX grew quarterly revenue 449.1% year over year.

    Bear case

    • SCNX beat EPS estimates in 37.5% of its last 8 reported quarters.

    SCNX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -201.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.50
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    SCNX Dividend

    Forward yield
    0.0%

    Frequently Asked Questions About SCNX

    Does SCNX pay dividends?

    Scienture Holdings, Inc. (SCNX) has a dividend payment track record. See the SCNX dividend history page for its current payment status, TTM yield, and recorded payments.

    What is SCNX's market cap?

    Scienture Holdings, Inc. (SCNX) has a market capitalization of $5.50M with a current stock price of $3.24.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In